このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Ipsen マネジメント

マネジメント基準チェック /44

Ipsen'sの CEO はDavid Loewで、 Jul2020年に任命され、の在任期間は 3.92年です。の年間総報酬は€ 4.36Mで、 22.6%給与と77.4%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.061%を直接所有しており、その価値は€ 6.03M 。経営陣と取締役会の平均在任期間はそれぞれ5.1年と10.5年です。

主要情報

David Loew

最高経営責任者

€4.4m

報酬総額

CEO給与比率	22.6%
CEO在任期間	4yrs
CEOの所有権	0.06%
経営陣の平均在職期間	5.2yrs
取締役会の平均在任期間	10.6yrs

経営陣の近況

We Think Shareholders May Consider Being More Generous With Ipsen S.A.'s (EPA:IPN) CEO Compensation Package

May 22

Recent updates

An Intrinsic Calculation For Ipsen S.A. (EPA:IPN) Suggests It's 42% Undervalued

Jun 16

Ipsen (EPA:IPN) Has Announced A Dividend Of €1.20

May 29

We Think Shareholders May Consider Being More Generous With Ipsen S.A.'s (EPA:IPN) CEO Compensation Package

May 22

CEO報酬分析

Ipsen の収益と比較して、David Loew の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Dec 31 2023	€4m	€988k	€617m
Jun 30 2023	n/a	n/a	€406m
Mar 31 2023	n/a	n/a	€500m
Dec 31 2022	€4m	€950k	€593m
Sep 30 2022	n/a	n/a	€656m
Jun 30 2022	n/a	n/a	€719m
Mar 31 2022	n/a	n/a	€675m
Dec 31 2021	€5m	€950k	€631m
Sep 30 2021	n/a	n/a	€626m
Jun 30 2021	n/a	n/a	€622m
Mar 31 2021	n/a	n/a	€585m
Dec 31 2020	€5m	€475k	€548m

報酬と市場: Davidの総報酬 ($USD 4.68M ) は、 French市場 ($USD 4.76M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Davidの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

David Loew (57 yo)

4yrs

在職期間

€4,361,753

報酬

Mr. David Loew has been the Chief Executive Officer & MD of Ipsen S.A. since July 1, 2020, and serves as its Director since May 28, 2020. Mr. Loew served as an Executive Vice President of Sanofi Pasteur at...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
David Loew	MD, CEO & Director	4yrs	€4.36m	0.061% € 5.8m
Aymeric Le Chatelier	Executive VP & CFO	9.7yrs	€1.02m	データなし
Aidan Murphy	Executive VP and Head of Technical Operations	6.5yrs	データなし	データなし
Craig Marks	Vice-President of Investor Relations	no data	データなし	データなし
Francois Garnier	Executive VP of Legal Affairs	9.6yrs	データなし	データなし
Gwenan White	Executive VP and Head of Communications	3.3yrs	データなし	データなし
Regis Mulot	Executive VP & Chief Human Resources Officer	6.3yrs	データなし	データなし
Dominique Bery	Head of Nordics & Baltics	7.3yrs	データなし	データなし
Bartosz Bednarz	Executive VP and Head of Global Product & Portfolio Strategy	3.8yrs	データなし	データなし
Philippe Lopes-Fernandes	Executive VP & Chief Business Officer	3.8yrs	データなし	データなし
James Levine	President of Fondation Ipsen	no data	データなし	データなし
Mari Scheiffele	Executive VP & President of International	2.7yrs	データなし	データなし

5.2yrs

平均在職期間

57.5yo

平均年齢

経験豊富な経営陣: IPNの経営陣は経験豊富で経験豊富です（平均在職期間は5.1年）。

取締役

名称	ポジション	在職期間	報酬	所有権
David Loew	MD, CEO & Director	4.2yrs	€4.36m	0.061% € 5.8m
Marc M. de Garidel	Non-Executive Chairman	13.7yrs	€600.00k	0.17% € 15.9m
Margaret Liu	Independent Director	7.1yrs	€130.00k	0.00083% € 78.7k
Michèle Ollier	Director	9.2yrs	€65.00k	0.00061% € 57.8k
Karen Witts	Independent Director	2.5yrs	€115.00k	0.00061% € 57.8k
Antoine Flochel	Vice Chairman	18.9yrs	€165.00k	0.0036% € 344.2k
Henri Beaufour	Director	18.9yrs	€36.00k	0% € 0
Anne Beaufour	Director	18.9yrs	€45.00k	26.41% € 2.5b
Carol Xueref	Director	12.1yrs	€115.00k	0.00061% € 57.8k
Philippe Bonhomme	Director	12.5yrs	€95.00k	0% € 0
Piet Wigerinck	Independent Director	6.2yrs	€78.00k	0.00082% € 77.8k
Laetitia Ducroquet	Employees Representative Director	3.7yrs	データなし	0.0010% € 94.8k

10.6yrs

平均在職期間

60.5yo

平均年齢

経験豊富なボード: IPNの取締役会は経験豊富で経験豊富です ( 10.5年の平均在任期間)。

Ipsen マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

We Think Shareholders May Consider Being More Generous With Ipsen S.A.'s (EPA:IPN) CEO Compensation Package

Ipsen Announces Executive Changes

Ipsen Appoints Catherine Abi-Habib as EVP Strategy, Transformation, and Digital

Recent updates

An Intrinsic Calculation For Ipsen S.A. (EPA:IPN) Suggests It's 42% Undervalued

Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis

Ipsen S.A. Approves Dividend, Payable on 3 June 2024

Ipsen (EPA:IPN) Has Announced A Dividend Of €1.20

Upcoming dividend of €1.20 per share

We Think Shareholders May Consider Being More Generous With Ipsen S.A.'s (EPA:IPN) CEO Compensation Package

Ipsen (EPA:IPN) Has Affirmed Its Dividend Of €1.20

Ipsen Announces Executive Changes

Ipsen (EPA:IPN) Has Affirmed Its Dividend Of €1.20

Dividend of €1.20 announced

There's Reason For Concern Over Ipsen S.A.'s (EPA:IPN) Price

Ipsen (EPA:IPN) Seems To Use Debt Quite Sensibly

Ipsen’s Onivyde Regimen, Potential New Standard-Of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ipsen Announces Latest Phase III Trial Data Investigating Cabometyx®? in Combination with Immunotherapy to Be Present at ASCO Gu 2024

Investors Still Waiting For A Pull Back In Ipsen S.A. (EPA:IPN)

These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC

Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial

Ipsen S.A. to Report Q4, 2023 Results on Feb 08, 2024

Ipsen S.A. to Report First Half, 2024 Results on Jul 24, 2024

Are Investors Undervaluing Ipsen S.A. (EPA:IPN) By 31%?

These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

IRLAB Therapeutics AB Announces Further Information on Results from Mesdopetam’s Clinical Phase IIb Study in Parkinson’s Disease Levodopa-Induced Dyskinesias and Phase III Preparatory Phase I Studies Performed by Ipsen

First half 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Profit margin trend

Ipsen Provides Update on E.U. Marketing Authorization Application for Bylvay for Cholestatic Pruritus in Patients with Alagille Syndrome

Ipsen Announces European Commission Decision on Palovarotene for the Treatment of FOP

Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease

Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 34% Undervaluation?

Ipsen Announces U.S. FDA Submission Acceptance of Its Supplemental New Drug Application for Onivyde Regimen in First-Line Metastatic Pancreatic Ductal Adenocarcinoma

Ipsen Announces U.S. FDA Approves Bylvay® for Patients Living with Cholestatic Pruritus Due to Alagille Syndrome

Ipsen to Present New Data

Ipsen (EPA:IPN) Is Due To Pay A Dividend Of €1.20

Ipsen S.A. Approves Dividend, Payable on 6 June 2023

Upcoming dividend of €1.20 per share at 1.1% yield

Ipsen's (EPA:IPN) Dividend Will Be €1.20

Ipsen S.A. Proposes Final Dividend for the Financial Year 2022, Payable on June 6, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Ipsen S.A. (EPA:IPN) Shares Could Be 48% Below Their Intrinsic Value Estimate

Ipsen (EPA:IPN) Has A Pretty Healthy Balance Sheet

Full year 2022 earnings: EPS and revenues miss analyst expectations

Ipsen S.A. Provides Earnings Guidance for the Full Year 2023

Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U

Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde(R) Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma At Asco GI

Ipsen (EPA:IPN) Ticks All The Boxes When It Comes To Earnings Growth

Ipsen S.A. (ENXTPA:IPN) entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $870 million.

Ipsen S.A. Provides Update on Phase III CONTACT-01 Trial Evaluating Cabozantinib

Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 46% Undervaluation?

Ipsen Announces Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

We Think Ipsen (EPA:IPN) Can Manage Its Debt With Ease

Ipsen S.A. Provides Earnings Guidance for the Financial Year 2023

Ipsen S.A. to Report Fiscal Year 2022 Results on Feb 09, 2023

Ipsen S.A. to Report Q2, 2023 Results on Jul 27, 2023

Ipsen S.A. to Report Q3, 2022 Results on Oct 26, 2022

Does Ipsen (EPA:IPN) Deserve A Spot On Your Watchlist?

Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde in Second-Line Monotherapy for Small Cell Lung Cancer

Does Ipsen (EPA:IPN) Have A Healthy Balance Sheet?

First half 2022 earnings released

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2022

Here's Why We Think Ipsen (EPA:IPN) Might Deserve Your Attention Today

Ipsen Announces U.S. FDA Priority Review for Palovarotene New Drug Application in Patients with Fibrodysplasia Ossificans Progressiva Following Resubmission

Ipsen Announces at ASCO 2022 New Cabometyx Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types

Ipsen (EPA:IPN) Will Pay A Larger Dividend Than Last Year At €1.20

Ipsen S.A. Approves Dividend, Payable on 2 June 2022

Ipsen S.A. Approves Dividend, Payable on 2 June 2022

Upcoming dividend of €1.20 per share

Ipsen S.A. Proposes Dividend for the Financial Year 2021, payable on 2 June 2022

Ipsen (EPA:IPN) Is Increasing Its Dividend To €1.20

Exelixis, Inc. Partner Ipsen Receives European Commission Approval for Cabometyx® (Cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Ipsen S.A. Provides Sales Guidance for the Year 2022

Ipsen's (EPA:IPN) Dividend Will Be Increased To €1.20

マネジメント基準チェック /44